MindBio Therapeutics Corp. announced the completion of manufacturing for its next-generation Edge AI Intoxication Detection Kiosk, a hardware platform designed to support the company’s proprietary Voice AI technology for identifying potential drug or alcohol impairment through vocal analysis. The announcement marks a step forward for MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), which is developing artificial intelligence-driven voice analytics as a rapid, non-invasive alternative to conventional screening methods.
The new kiosk builds on a prototype developed in June. MindBio is continuing software integration, system testing and validation of its predictive models against established breath alcohol and oral fluid testing methods. According to the company, the AI prediction model uses more than 50 million data points to predict alcohol intoxication with remarkable accuracy based solely on the human voice. A potential initial commercial pilot is targeted for later this year, which would allow the technology to be evaluated in a real-world environment against existing testing methods.
The development matters because workplace drug and alcohol screening has long relied on methods that can be time-consuming, invasive and costly to administer at scale. MindBio aims to enable more frequent, large-scale screening while potentially reducing testing costs, administration time and operational disruptions. The company is targeting safety-sensitive industries including mining, aviation, construction, heavy transport and law enforcement, where impairment detection is critical to safety and compliance.
“The completion of manufacturing for our next-generation Edge AI Intoxication Detection Kiosk is a significant milestone,” the company said in its announcement. MindBio is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis, and is developing an enterprise platform that integrates bespoke hardware and software for use in a range of enterprise environments.
For investors and industry observers, the planned pilot represents a key test of whether voice-based impairment detection can perform reliably outside controlled settings. If successful, the technology could offer employers a faster, less intrusive option for routine screening, though validation against conventional methods will be essential for regulatory and operational acceptance. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.
The announcement was disseminated through TechMediaWire, a communications platform focused on technology companies. TechMediaWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. For full terms and disclaimers, see https://www.TechMediaWire.com/Disclaimer.
